{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T19:21:08Z","timestamp":1774466468105,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.amjms.2022.04.018","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T12:09:23Z","timestamp":1650629363000},"page":"461-465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Romosozumab used to treat a patient with cystic fibrosis-related osteoporosis"],"prefix":"10.1016","volume":"364","author":[{"given":"Hanna M.","family":"Crow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leland","family":"Graves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abeer","family":"Anabtawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.amjms.2022.04.018_bib0001","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1056\/NEJMc1502191","article-title":"Origins of cystic fibrosis lung disease","volume":"372","author":"Stoltz","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.amjms.2022.04.018_bib0002","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/thx.2005.046516","article-title":"Controlled longitudinal study of bone mass accrual in children and adolescents with cystic fibrosis","volume":"61","author":"Buntain","year":"2006","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.amjms.2022.04.018_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00223-009-9316-9","article-title":"The prevalence of osteoporosis, osteopenia, and fractures among adults with cystic fibrosis: a systematic literature review with meta-analysis","volume":"86","author":"Paccou","year":"2010","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"10.1016\/j.amjms.2022.04.018_bib0004","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1210\/jc.2016-3459","article-title":"Accrual of bone mass in children and adolescents with cystic fibrosis","volume":"102","author":"Sharma","year":"2017","journal-title":"J Clin Endocrinol Metabol"},{"issue":"Suppl 2","key":"10.1016\/j.amjms.2022.04.018_bib0005","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/j.jcf.2019.08.022","article-title":"Vitamin D deficiency and its treatment in cystic fibrosis","volume":"18","author":"Daley","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"9","key":"10.1016\/j.amjms.2022.04.018_bib0006","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/thorax.55.9.798","article-title":"Osteoporosis and osteopenia in adults and adolescents with cystic fibrosis: prevalence and associated factors","volume":"55","author":"Conway","year":"2000","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.amjms.2022.04.018_bib0007","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1359\/JBMR.051106","article-title":"BMD and body composition in children and young patients affected by cystic fibrosis","volume":"21","author":"Bianchi","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.1016\/j.amjms.2022.04.018_bib0008","doi-asserted-by":"crossref","first-page":"186","DOI":"10.7326\/0003-4819-128-3-199802010-00004","article-title":"Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis","volume":"128","author":"Aris","year":"1998","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.amjms.2022.04.018_bib0009","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1210\/jc.2004-1629","article-title":"Guide to bone health and disease in cystic fibrosis","volume":"90","author":"Aris","year":"2005","journal-title":"J Clin Endocrinol Metabol"},{"issue":"1","key":"10.1016\/j.amjms.2022.04.018_bib0010","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1164\/rccm.200307-1049OC","article-title":"Efficacy of alendronate in adults with cystic fibrosis with low bone density","volume":"169","author":"Aris","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.amjms.2022.04.018_bib0011","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2265.2008.03434.x","article-title":"Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF)","volume":"70","author":"Chapman","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"10.1016\/j.amjms.2022.04.018_bib0012","doi-asserted-by":"crossref","DOI":"10.1378\/chest.08-0608","article-title":"Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS Trial)","volume":"134","author":"Papaioannou","year":"2008","journal-title":"Chest"},{"issue":"Suppl 2","key":"10.1016\/j.amjms.2022.04.018_bib0013","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/j.jcf.2019.08.017","article-title":"Cystic fibrosis bone disease treatment: Current knowledge and future directions","volume":"18","author":"Putman","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.amjms.2022.04.018_bib0014","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bone.2019.01.003","article-title":"Outcomes following intravenous bisphosphonate infusion in pediatric patients: A 7-year retrospective chart review","volume":"121","author":"Nasomyont","year":"2019","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.amjms.2022.04.018_bib0015","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S2213-2600(13)70064-X","article-title":"Treatment of low bone density in young people with cystic fibrosis: a multicentre, prospective, open-label observational study of calcium and calcifediol followed by a randomised placebo-controlled trial of alendronate","volume":"1","author":"Bianchi","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"Suppl 2","key":"10.1016\/j.amjms.2022.04.018_bib0016","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S1569-1993(11)60004-0","article-title":"European cystic fibrosis bone mineralisation guidelines","volume":"10","author":"European guidelines ref Sermet-Gaudelus","year":"2011","journal-title":"J Cyst Fibros"},{"issue":"9142","key":"10.1016\/j.amjms.2022.04.018_bib0017","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/S0140-6736(05)79826-3","article-title":"Severe bone pain after intravenous pamidronate in adult patients with cystic fibrosis","volume":"352","author":"Haworth","year":"1998","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.amjms.2022.04.018_bib0018","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/(SICI)1096-9926(199908)60:2<68::AID-TERA10>3.0.CO;2-H","article-title":"Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats","volume":"60","author":"Patlas","year":"1999","journal-title":"Teratology"},{"key":"10.1016\/j.amjms.2022.04.018_bib0019","article-title":"Evaluation of teriparatide for treatment of osteoporosis in four patients with cystic fibrosis: a case series","volume":"2014","author":"Siwamogsatham","year":"2014","journal-title":"Case Rep Endocrinol"},{"key":"10.1016\/j.amjms.2022.04.018_bib0020","series-title":"Forteo (teriparatide) [package insert]","year":"2020"},{"key":"10.1016\/j.amjms.2022.04.018_bib0021","series-title":"Evenity (romosozumab-aqqg) [package insert]","year":"2019"},{"issue":"16","key":"10.1016\/j.amjms.2022.04.018_bib0022","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"9358","key":"10.1016\/j.amjms.2022.04.018_bib0023","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(03)12567-6","article-title":"Cystic fibrosis","volume":"361","author":"Ratjen","year":"2003","journal-title":"Lancet"},{"issue":"29","key":"10.1016\/j.amjms.2022.04.018_bib0024","doi-asserted-by":"crossref","first-page":"18009","DOI":"10.1074\/jbc.M115.646208","article-title":"Increased NF-\u03baB Activity and Decreased Wnt\/\u03b2-Catenin Signaling Mediate Reduced Osteoblast Differentiation and Function in \u0394F508 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mice","volume":"290","author":"Le Henaff","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.amjms.2022.04.018_bib0025","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962922001793?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962922001793?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:41:38Z","timestamp":1757702498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962922001793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0002962922001793"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2022.04.018","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Romosozumab used to treat a patient with cystic fibrosis-related osteoporosis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2022.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}